- AstraZeneca's upcoming earnings report predicts an EPS decline, yet anticipates revenue growth.
- Analyst forecasts imply significant potential upside for AstraZeneca's stock price.
- GuruFocus metrics suggest AstraZeneca is currently undervalued with promising future growth.
AstraZeneca PLC (AZN, Financial) is gearing up to release its first-quarter earnings on April 29. Analysts anticipate a notable drop in earnings per share (EPS), projected to decline by 46.1% to $1.11. However, the forecasted revenue tells a different story, expected to climb by 8.2% to $13.72 billion. Historically, AstraZeneca has a solid track record of outperforming both earnings and revenue expectations, a factor that investors will be keenly observing.
Wall Street Analysts Forecast
According to insights from 11 analysts, AstraZeneca PLC (AZN, Financial) boasts an average one-year price target of $100.32. This range includes a high forecast of $230.64 and a low forecast of $67.00, suggesting an impressive upside of 44.03% from its current trading price of $69.65. For more in-depth forecast data, visit the AstraZeneca PLC (AZN) Forecast page.
Consensus from 13 brokerage firms positions AstraZeneca PLC (AZN, Financial) with an average recommendation rating of 1.8, categorizing it as "Outperform." The rating scale varies from 1, indicating a Strong Buy, to 5, indicating a Sell.
Utilizing GuruFocus estimates, AstraZeneca PLC's (AZN, Financial) projected GF Value over the next year is $87.35. This estimate suggests a potential upside of 25.41% from the current price of $69.65. The GF Value metric represents GuruFocus' fair value assessment based on historical stock multiples, past business growth, and future performance forecasts. Investors can explore more detailed data on the AstraZeneca PLC (AZN) Summary page.
